Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Phase 2

Completed

Conditions: Central Nervous System Pathology

Interventions: Drug: Gadoquatrane (BAY1747846)
Drug: Gadobutrol (Gadovist/Gadavist)

Registration Number: NCT04307186

Lead Sponsor: Bayer

Brief Summary: Researchers in this study want to find the appropriate dose of drug BAY1747846 for adults undergoing MRI for known or highly suspected brain and/or spinal cord conditions so that the image quality is similar to that of drug gadobutrol for adults undergoing MRI. MRI stands for Magnetic resonance imaging which produces body pictures created by using magnetic energy rather than x-ray energy.

Both BAY1747846 and gadobutrol are medicinal products known as gadolinium-based contrast agents (GBCA) which are used in MRI examinations to provide contrast enhancement and improve imaging performance. Gadobutrol (brand name: Gadavist, Gadovist) has been approved worldwide for the diagnosis of various disorders in adult and pediatric patients. BAY1747846 is a new GBCA under development with the goal to provide similar imaging performances in MRI. Participants in this study will receive both BAY1747846 and gadobutrol with a period of 3 - 14 days in between. A MRI examination will be performed after each injection. Participant will stay in this study for 2 - 4 weeks depending on the scheduling of the visits.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 57

Inclusion Criteria

Participant must be at least 18 years of age at the time of signing the informed consent.
Known or highly suspected CNS pathology (contrast-enhancing CNS lesion) referred for contrast-enhanced MRI of the CNS.
Male and female.
Estimated glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m^2.

Exclusion Criteria

Considered clinically unstable or has a concomitant/intercurrent condition (e.g. COVID-19 infection) that would not allow participation for the full planned study period (i.e. period 1, 2 or both) in the judgement of the investigator.
Severe cardiovascular disease.
Patients undergoing liver transplantation.
Any contraindication to MRI examinations.
History of severe allergic or anaphylactic/anaphylactoid reaction to any allergen including drugs and contrast agents, foods, chemicals or other substances.
History of allergic asthma and/ or atopic dermatitis.
Suspected lesions or suffering from any of the following CNS diseases/lesion types as the main indication for MRI:
- Lepto-meningeal disease (e.g. leptomeningeal carcinomatosis). Dural lesions (e.g. meningiomas) fulfilling inclusion criteria #2 are not excluded
- Pituitary adenomas (macro and micro)
- Tumors of the choroid plexus
- Tumors of the pineal gland
- Dermoid/epidermoid tumors
- Infectious disease (e.g. brain abscess, cisticercosis, etc.)
- Venous angiomas
- Subacute/chronic ischemia
- Encephalitis
- Multiple sclerosis (acute and chronic)
- Optic neuritis
- Chordomas
- Von Hippel Lindau syndrome
- Hypertensive leukoencephalopathy.
Receipt of any contrast agent < 72 h prior to the study MRIs, or planned receipt of any contrast agent within 72 h after the second study MRI.
Planned or expected biopsy in the region of interest or any interventional therapeutic procedure from the first study MRI up to 24 h after the second study MRI.
Planned or expected change in any treatment or procedure between the two study MRIs that may alter image comparability and /or chemotherapy which is changed between the two MRI procedures.
Contraindications to the administration of gadobutrol, as specified in the local product label.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Gadobutrol + Gadoquatrane	Gadoquatrane (BAY1747846)	Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of Gadoquatrane (BAY1747846).
Gadobutrol + Gadoquatrane	Gadobutrol (Gadovist/Gadavist)	Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of Gadoquatrane (BAY1747846).

Primary Outcome Measures

Name	Time	Method
Overall Diagnostic Preference	At 5 minute post each injection	Overall diagnostic preference using a matched pairs approach was evaluated by 3 blinded readers using an ordinal 5-point scale (greatly prefer gadoquatrane, prefer gadoquatrane, no preference, prefer gadobutrol, greatly prefer gadobutrol). Percentage of participants and the respective Wald confidence intervals (CI) for image preference were reported for each of the 3 readers based on the 3-point preference scale (1=greatly prefer/prefer gadoquatrane, 0=no preference, -1=greatly prefer/prefer gadobutrol). If 2 or 3 readers reach the same conclusion on the recommended action (e.g. no dose adjustment needed), then this will be the recommended action taken.

Secondary Outcome Measures

Name	Time	Method
Sum of Lesion Visualization Parameters on Post-contrast Images	At 5 minute post each injection	The 3 lesion visualization parameters (border delineation/degree of contrast enhancement/internal morphology) were combined by adding them up for each participant and each blinded reader, leading to only one variable on an ordinal 11-point scale (the higher values represent a better lesion visualization). Average reader was the mean of the 3 blinded readers averages of the scores per participant. Lesion border delineation: measured on a 4-point scale (1=None \[no/unclear delineation of the lesion boundaries\] to 4=Excellent \[clear and complete delineation\]). Degree of lesion contrast enhancement: measured on a 4-point scale (1=No \[lesion is not enhanced\] to 4=Excellent \[lesion is clearly and brightly enhanced\]). Lesion internal morphology: measured on a 3-point scale (1=Poor \[structure and internal morphology of the lesion is poorly visible\] to 3=Good \[structure and internal morphology of the lesion is sufficiently visible\]).
Lesion Visualization Parameter Border Delineation on Pre-contrast and Combined Pre- and Post-contrast Images	At pre-injection and 5 minute post each injection	Lesion border delineation: up to 5 of the largest lesions were selected and scored using a 4-point scale (1=None \[no/unclear delineation of the lesion boundaries\] to 4=Excellent \[clear and complete delineation\]; the higher values represent a better lesion border delineation). Average reader was the mean of the 3 blinded readers averages of the scores per participant.
Lesion Visualization Parameter Contrast Enhancement on Pre-contrast and Combined Pre- and Post-contrast Images	At pre-injection and 5 minute post each injection	Degree of lesion contrast enhancement: up to the 5 largest lesions were selected and scored using a 4-point scale (1=No \[lesion is not enhanced\] to 4=Excellent \[lesion is clearly and brightly enhanced\]; the higher values represent a better degree of lesion contrast enhancement). Average reader was the mean of the 3 blinded readers averages of the scores per participant.
Lesion Visualization Parameter Internal Morphology on Pre-contrast and Combined Pre- and Post-contrast Images	At pre-injection and 5 minute post each injection	Lesion internal morphology: up to 5 of the largest lesions were selected and scored using a 3-point scale (1=Poor \[structure and internal morphology of the lesion is poorly visible\] to 3=Good \[structure and internal morphology of the lesion is sufficiently visible\]; the higher values represent a better lesion internal morphology). Average reader was the mean of the 3 blinded readers averages of the scores per participant.
Number of Lesions on Pre-contrast and Combined Pre- and Post-contrast Images	At pre-injection and 5 minute post injection	The 3 blinded readers recorded the total number of lesions for each pre-contrast and combined pre- and post-contrast magnetic resonance image set separately. The numbers of participants by number of detected lesions were reported.

Trial Locations

Locations (17): UMHAT Sveti Georgi
🇧🇬
Plovdiv, Bulgaria
University Multiprofile Hosp. for Active Treat. Sveti Ivan
🇧🇬
Sofia, Bulgaria
National Hospital Organization Kanmon Medical Center
🇯🇵
Shimonoseki, Yamaguchi, Japan
Universitätsklinikum Essen
🇩🇪
Essen, Nordrhein-Westfalen, Germany
Northwestern University
🇺🇸
Chicago, Illinois, United States
Hiroshima City Hiroshima Citizens Hospital
🇯🇵
Hiroshima, Japan
Acibadem City Clinic Multiprofile Hospital for Active Treatm
🇧🇬
Sofia, Bulgaria
University of Iowa Hospitals & Clinics
🇺🇸
Iowa City, Iowa, United States
Hyogo Prefectural Nishinomiya Hospital
🇯🇵
Nishinomiya, Hyogo, Japan
Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital
🇯🇵
Fukuoka, Japan
National Hospital Organization Kyushu Medical Center
🇯🇵
Fukuoka, Japan
MVZ Prof. Uhlenbrock und Partner
🇩🇪
Dortmund, Nordrhein-Westfalen, Germany
Friedrich-Schiller-Uni. Jena
🇩🇪
Jena, Thüringen, Germany
Hokkaido University Hospital
🇯🇵
Sapporo, Hokkaido, Japan
National Hospital Organization Himeji Medical Center
🇯🇵
Himeji, Hyogo, Japan
Kishiwada Tokushukai Hospital
🇯🇵
Kishiwada, Osaka, Japan
Penn State Milton S. Hershey Medical Center
🇺🇸
Hershey, Pennsylvania, United States